Nonintubated Uniportal Video-Assisted Thoracic Surgery for Chest Infections
Chest infection is a health care problem in many regions of the world, and pleural empyema is the most common type of surgical chest infection. In the past decennium, the…
Treatment of Pleural Effusions with Nonintubated Video-Assisted Thoracoscopic Surgery
Video-assisted thoracic surgery has considerably improved the care of the thoracic surgical patient. Patients are able to leave the hospital sooner and experience less pain with equal oncologic outcomes when…
Nonintubated Video-Assisted Thoracoscopic Surgery Lung Biopsy for Interstitial Lung Disease
Interstitial lung diseases are a heterogeneous group with diffuse parenchymal lung disease. Because most patients with interstitial lung diseases have impaired pulmonary function, the risks of thoracic surgery are an…
Nonintubated Video-Assisted Thoracic Surgery for the Management of Primary and Secondary Spontaneous Pneumothorax
Nonintubated video-assisted thoracoscopic surgery for the treatment of primary and secondary pneumothorax was first reported in 1997 by Nezu. However, studies on this technique are few. Research in the past…
Combining Immunotherapy and Chemotherapy for Non–Small Cell Lung Cancer
Over the past year, the combination of platinum-based chemotherapy and immunotherapy has become the standard of care for patients with metastatic non–small-cell lung cancer with any programmed death ligand 1…
Principles of Immunotherapy in Non-Small Cell Lung Cancer
Immunotherapy has transformed the treatment of many tumors. Robust data demonstrating improved overall survival and progression-free survival in patients treated with monoclonal antibodies have established immune checkpoint inhibitors as standard…
Adjuvant Chemotherapy
Five-year survival rates for patients with early-stage non–small cell lung cancer have room for improvement. Adjuvant chemotherapy results in a small but significant increase in overall survival at 5 years. Efforts…
Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer
Liquid biopsies for the diagnosis and treatment of lung cancer have developed rapidly, driven primarily by technical advances in sensitivity to detect circulating tumor DNA (ctDNA). Still, technical limitations such…
Molecular Targets Beyond the Big 3
Lung cancer is a heterogeneous genomic disease. Smoking remains the primary cause. Genetic susceptibility and environmental exposures are responsible for 10% to 15% of cases. Targeted therapies improve survival in…
ROS1-rearranged Non–small Cell Lung Cancer
ROS1-rearranged non–small cell lung cancer (NSCLC) makes up approximately 1% to 2% of all NSCLC, is oncogenically driven by a constitutively activated ROS1 kinase paired with certain fusion partners, and…
